We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERE
26
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$3.82M 0.72%
93,350
+69,091
+285% +$2.88M
CRNX icon
27
Crinetics Pharmaceuticals
CRNX
$8.84B
$3.35M 0.63%
+74,850
New +$3.46M
BIL icon
28
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$47.1B
$2.98M 0.56%
32,500
– –
INSM icon
29
Insmed
INSM
$21.4B
$2.83M 0.53%
+42,217
New +$1.64M
QTTB icon
30
Q32 Bio
QTTB
$466M
$2.81M 0.53%
156,504
-31,063
-17% -$743K
GRCE
31
Grace Therapeutics
GRCE
$33.8M
$2.8M 0.53%
959,571
+742,190
+341% +$2.24M
VUSB icon
32
Vanguard Ultra-Short Bond ETF
VUSB
$8.94B
$2.73M 0.52%
55,206
– –
JPST icon
33
JPMorgan Ultra-Short Income ETF
JPST
$40.1B
$2.73M 0.51%
54,000
– –
SHV icon
34
iShares 0-1 Year Treasury Bond ETF
SHV
$20.8B
$2.71M 0.51%
24,500
– –
SVRA icon
35
Savara
SVRA
$1.12B
$2.67M 0.5%
663,598
+657,998
+11,750% +$2.93M
OABI icon
36
OmniAb
OABI
$287M
$2.67M 0.5%
712,560
+261,075
+58% +$1.19M
USFR icon
37
WisdomTree Floating Rate Treasury Fund
USFR
$18.1B
$2.67M 0.5%
53,000
– –
ACHV icon
38
Achieve Life Sciences
ACHV
$659M
$2.55M 0.48%
542,233
-332,767
-38% -$1.6M
CNTA
39
DELISTED
Centessa Pharmaceuticals
CNTA
$2.29M 0.43%
253,197
+46,341
+22% +$440K
FULC icon
40
Fulcrum Therapeutics
FULC
$273M
$2.28M 0.43%
368,369
+28,544
+8% +$216K
KALA icon
41
KALA BIO
KALA
$14.1M
$2.17M 0.41%
+6,121
New +$2.02M
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$5.8B
$2.13M 0.4%
114,309
+54,609
+91% +$1.02M
CERE
43
PUT
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$2.05M 0.39%
50,200
– –
ULST icon
44
State Street Ultra Short Term Bond ETF
ULST
$527M
$1.93M 0.36%
47,684
– –
BEAM icon
45
Beam Therapeutics
BEAM
$2.63B
$1.71M 0.32%
+72,800
New +$1.79M
CLRB icon
46
Cellectar Biosciences
CLRB
$20.5M
$1.71M 0.32%
22,736
+1,318
+6% +$126K
TEVA icon
47
Teva Pharmaceuticals
TEVA
$40.8B
$1.68M 0.32%
103,121
+1,495
+1% +$23K
DCTH icon
48
Delcath Systems
DCTH
$422M
$1.66M 0.31%
198,347
-20,626
-9% -$131K
SLNO
49
DELISTED
Soleno Therapeutics
SLNO
$1.63M 0.31%
+39,929
New +$1.69M
APGE icon
50
Apogee Therapeutics
APGE
$10.1B
$1.61M 0.3%
40,875
+34,875
+581% +$1.69M
1
2
3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.